Navigate today’s most pressing health industry challenges with a leading global expert by your side.
Discover intelligent digital solutions to help improve outcomes, manage costs, and solve the toughest healthcare challenges.
Meet growing needs for innovative insurance solutions while increasing operational health and improving compliance.
Financial modeling & industrialization
Insurance risk assessment
Retirement & Benefits
Deliver on the promises of the past and create smart solutions for the future.
Compensations & benefits
Benefit plan evaluation
Manage complex risks using data-driven insights, advanced approaches, and deep industry experience.
Auto policy underwriting
Software performance enhancement
Mortgage platform for investments & reinsurance
Solvency II reporting & compliance
This is a place where your ideas and insights make an impact. Where an independent, entrepreneurial spirit is an advantage. And where diversity of thought and experience makes us who we are.
Data-driven insight. Deep expertise. Transformative innovation. Since 1947, Milliman has delivered intelligent solutions to improve health and financial security.
From negotiated drug prices to Medicare Part D redesign, the law will transform a key health benefit program
It’s the most significant change to prescription drug financing since the creation of Medicare Part D. Enacted in 2022, the Inflation Reduction Act will gradually phase in key amendments, including government negotiation of drug prices, a new cap on Medicare Part D cost sharing, and penalties for pharmaceutical manufacturers that raise prices faster than inflation. Our research and analysis break down the implications and offer guidance to help health plans, pharmacy benefit managers, and pharmaceutical companies adapt.
Get an overview of the law’s main changes to Medicare and other healthcare markets, and a timeline for implementation.
Milliman healthcare leaders discuss the law’s provisions and their potential impact on payers, drugmakers, and other stakeholders.
The Inflation Reduction Act requires drug manufacturers to negotiate prices with the federal government, a change with wide-ranging implications for the pharmaceutical industry and healthcare payers.
As drugmakers adapt to insulin copay caps, rebate penalties, and more regulatory provisions that impact pricing, we lay out key items to watch and offer preparation strategies.
Milliman’s actuaries analyzed how the new Medicare Part D benefit redesign will affect plan liability and risk for health plan sponsors and present risk-mitigation strategies.
We discuss how the Inflation Reduction Act could affect Medicare Part D plans, members, the government, and pharmaceutical manufacturers.
We examine potential ramifications of the Inflation Reduction Act, which may drive the biggest changes in prescription drug coverage since Medicare Part D.
Understanding how the IRA lets beneficiaries smooth their cost sharing over the plan year.
We offer a primer on the Medicare Part D prescription drug rebates, with insights into the possible impact of the Inflation Reduction Act.
As more IRA changes take effect, these areas may require additional analysis for payers.
With expertise in payer, pharmacy benefit management (PBM), and integrated delivery networks (IDNs), we can help you identify access opportunities specific to your products.
Facilitate rate development, ensure feasibility, implement communications strategies, and more with dedicated Part D expertise.
Choose the right pharmacy benefits management vendor and develop effective benefit plans.
Evaluate relative values of Medicare Advantage program plans using a comprehensive, Excel-based tool.
Our solutions are tailored to your needs, whether you’re focused on small molecule pharma, gene and cell therapies, rare disease, biosimilars, or medical devices.
Ask the tough questions. We’re ready for them.